Travis Molloy BSc.
Travis' background lies in over 15 years of Biotech and Pharmaceutical experience, ranging from research and pharmaceutical production in companies such as CSL, to executive and board positions in a range of Biotech's. Prior to Xeophin, he was a Co-founder and Executive Chairman of Sementis Ltd, a successful Australian Biotech specialising in genetic approaches to allergies and infectious disease. His unique strengths in Biotech stem from his background in leadership roles within Australian and International organisations. These roles included consulting on Leadership, Change Management and Executive Development in companies such as BP, Standard & Poor, the Australian Defense Force, Local Government and a range of other Australian top 500s.
Chief Executive Officer & Managing Director
Troy is an experienced and passionate Biotechnology Entrepreneur with a track record of successful start-ups and consultancy in Australia and abroad. Prior to starting Xeophin, Troy was the CEO and Co-founder of Sementis Ltd, a successful Australian Biotech specialising in gene therapies for allergies and infectious disease. His strengths lie in establishing collaborations and ‘deals’ in the Biotech and Pharmaceutical space. His engineering background can be seen in his methodical and detail orientated approach to technical collaborations and transactional work. Prior to his decade of Biotech Executive and Directorial roles, Troy has consulted to Australian and International companies such as Tenix, Energex, Parsons Brinckerhoff and Worley Parsons, and led multisite teams across continents. Troy is currently studying for an MBA with Griffith University.
Vice President - Finance
Jason has over twenty-five years experience in various Management, Executive and Board roles in diverse industries including extensive experience in both Board and Executive Management roles in listed Australian biotech companies. Jason has been responsible for the operational oversight of many large clinical trial programs, negotiating research and development collaborations with major pharma companies, and raising in excess of over $120M through capital raising initiatives for both listed and private companies. Jason brings expertise in managing all aspects of listed biotechnology companies, and has built strong connections at the Board and Executive level with some of the largest global Pharma companies.